$SLP News

Is It Too Late To Consider Buying Simulations Plus, Inc. (NASDAQ:SLP)?

Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference

This Analyst Just Made A Huge Upgrade To Their SLP Resources Berhad (KLSE:SLP) Earnings Forecasts

Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows

Do Options Traders Know Something About Simulations Plus Stock We Don't?

Biosimulation Market Research and Global Forecast Report 2026-2036: Expansion Driven by Precision Medicine, AI-Powered In-Silico Drug Development and Rising Demand for Cost-Efficient Clinical Trials

Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products

Simulations Plus Partners With Lonza Group, FDA To Develop, Validate Framework For Amorphous SOLID Dispersion Drug Products

Simulations Plus Expands Global Access to Model-Informed Drug Development Training Through Its 2026 Spring School

Here’s Simulations Plus Inc (SLP)’s Vision for AI in Drug Development

How The Sylvania Platinum (AIM:SLP) Story Is Shifting As Valuation Tweaks Meet New Guidance

Simulations Plus: Better Quarter, Same Doubts

Simulations Plus Q2 Earnings Call Highlights

Simulations Plus: Down Substantially, Not An Automatic Buy

What's Going On With Simulations Plus Stock Friday?

Simulations Plus, Inc. Q2 2026 Earnings Call Summary

TD Cowen Maintains Hold on Simulations Plus, Lowers Price Target to $16

Simulations Plus shares are trading higher after the company reported better-than-expected Q2 financial results.

Simulations Plus Inc (SLP) Q2 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results